MLA
ALNY icon

MB, Levis & Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

MB, Levis & Associates’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35
Closed -$11.4K – 245
2025
Q2 		$11.4K Buy
+35
New +$9.69K 0.01% 186

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

MB, Levis & Associates's ALNY Position: Q3 2025 in Review

MB, Levis & Associates sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 35 shares — an estimated $11.4K sold.

MB, Levis & Associates first reported a position in ALNY in Q2 2025 and held it in 1 quarter. The position peaked at $11.4K in Q2 2025. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • MB, Levis & Associates reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • MB, Levis & Associates sold 35 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $11.4K.
  • MB, Levis & Associates first reported a position in Alnylam Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • MB, Levis & Associates's Alnylam Pharmaceuticals position peaked at $11.4K in Q2 2025.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on MB, Levis & Associates's 13F filing for Q3 2025, filed 15 Oct 2025.